Table 2.
Median survival and hazard ratio of baseline composite ESAS scores
| Median survival, mo (95% CI) | Crude hazard ratio (95% CI) | ||
|---|---|---|---|
| High symptom burden | Low symptom burden | ||
| Total cohort (n = 2034) | |||
| TSDS | 4.64 (3.95, 5.20) | 7.46 (7.07, 8.06) | 1.54 (1.39, 1.70)* |
| PHS | 4.14 (3.68, 4.80) | 7.60 (7.13, 8.12) | 1.64 (1.48, 1.81)* |
| PSS | 5.56 (5.10, 6.08) | 7.10 (6.71, 7.60) | 1.23 (1.11, 1.36)* |
| Gemcitabine (n = 1103) | |||
| TSDS | 3.66 (3.32, 4.21) | 6.81 (6.21, 7.27) | 1.57 (1.37, 1.78)* |
| PHS | 3.37 (2.80, 3.81) | 6.94 (6.35, 7.53) | 1.71 (1.50, 1.95)* |
| PSS | 4.95 (3.95, 5.56) | 6.21 (5.49, 6.71) | 1.20 (1.05, 1.37)* |
| Gemcitabine+nab‐paclitaxel (n = 131) | |||
| TSDS | 4.37 (2.00, 5.92) | 6.18 (4.60, 7.30) | 1.30 (0.86, 1.95) |
| PHS | 3.65 (1.58, 5.92) | 6.18 (4.67, 7.30) | 1.28 (0.85, 1.93) |
| PSS | 4.70 (3.26, 6.15) | 6.15 (4.41, 7.43) | 1.36 (0.92, 2.02) |
| FOLFIRINOX (n = 809) | |||
| TSDS | 6.12 (5.23, 7.04) | 8.84 (8.19, 9.63) | 1.44 (1.21, 1.72)* |
| PHS | 6.31 (5.26, 7.20) | 8.81 (8.19, 9.63) | 1.51 (1.27, 1.81)* |
| PSS | 6.97 (5.98, 7.96) | 8.52 (7.86, 9.50) | 1.25 (1.05, 1.48)* |
Abbreviations: CI, confidence interval; TSDS, baseline total symptom distress score; PHS, baseline physical symptom scores; PSS, baseline psychological symptom scores.
*
P < .05.